Efficacy of DMARDs and methylprednisolone treatment on the gene expression levels of HSPA5, MMD, and non-coding RNAs MALAT1, H19, miR-199a-5p, and miR-1-3p, in patients with rheumatoid arthritis

• Published in: International immunopharmacology Vol. 108; p. 108878
• Main Authors: Mahmoudi, Zahra, Karamali, Negin, Roghani, Seyed Askar, Assar, Shirin, Pournazari, Mehran, Soufivand, Parviz, Salari, Farhad, Rezaiemanesh, Alireza
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.07.2022
• Subjects: DMARDs; HSPA5; MMD; ncRNAs; Rheumatoid arthritis; MEG3; lncRNA; JNK; FACS; DMARDs; Anti-CCP; ncRNA; ncRNAs; ETS1; TNF; TH17 cell; AUC; NF-κB; HIF1-α; IRE1; miRNA; PAQR1; WBC; cDNA; ROC curve; RT-qPCR; DAS28; HSPA5; circRNA; MMD; ESR; MACS; STAT3; mPRED; MAPK; NEAT1; ER; PBMC; IL-6; RA; ACR; PICSAR; APC; Rheumatoid arthritis; EULAR; MALAT1; ATF6; XBP1s
• DOI: 10.1016/j.intimp.2022.108878
• ISSN: 1567-5769

•MALAT1 and H19 may be candidates as potential biomarkers in rheumatoid arthritis.•MALAT1 and H19 positively correlated with MMD and RA severity.•DMARDs plus mPRED were not effective in reducing HSPA5 and MMD gene expression. Rheumatoid arthritis (RA) is a systemic autoimmune disease with chronic inflammation characterized by joint damage and even extra-articular involvement. In this study, the gene expression levels of MALAT1, H19 and their possible downstream microRNAs, miR-199a-5p, miR-1-3p, and the predicted targets of these miRNAs, HSPA5 and MMD, were examined. Twenty-five newly diagnosed RA patients and 25 healthy individuals were included. For six months, patients were treated with conventional disease-modifying antirheumatic drugs (DMARDs) and Methylprednisolone (mPRED). Blood samples were obtained from healthy controls and patients (before and after treatment). After RNA extraction, the RT-qPCR technique was used to evaluate the expression level of the studied genes. Data showed that the expression level of MALAT1, H19, miR-199a-5p, and miR-1-3p was significantly higher in the newly diagnosed patients with RA than the healthy subjects, but the increase in the expression level of HSPA5 and MMD genes in the new cases was not significant compared to healthy controls. After treatment, except for the expression level of lncRNAs, the expression level of miRNAs, HSPA5, and MMD significantly increased. Based on ROC curve analysis of MALAT1, H19, miR-199a-5p and miR-1-3p have a high ability to identify patients from healthy individuals (AUC = 0.986, AUC = 0.995, AUC = 0.855, AUC = 0.675, respectively). MALAT1 and H19 may be candidates as potential biomarkers for the discrimination between RA patients and controls. DMARDs plus mPRED therapy do not have a desirable effect on reducing inflammatory responses and ER stress.